中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
3期
215-220
,共6页
蔡小矜%宋阿霞%王华%张平%张桂新%扬帆%魏嘉璘%马巧玲%阎嶂松
蔡小矜%宋阿霞%王華%張平%張桂新%颺帆%魏嘉璘%馬巧玲%閻嶂鬆
채소긍%송아하%왕화%장평%장계신%양범%위가린%마교령%염장송
白细胞介素18%多态性,单核苷酸%造血干细胞移植%移植物抗宿主病
白細胞介素18%多態性,單覈苷痠%造血榦細胞移植%移植物抗宿主病
백세포개소18%다태성,단핵감산%조혈간세포이식%이식물항숙주병
Interleukin-18%Polymorphism,single nucleotide%Hematopoietic stem cell transplantation%Graft versus host disease
目的 研究IL-18基因启动子区单核苷酸多态性(SNP)对恶性血液病患者HLA匹配同胞供者异基因造血干细胞移植(allo-HSCT)造血重建、并发症及生存的影响.方法 93例恶性血液病患者纳入研究.采用序列特异性引物聚合酶链反应(PCR-SSP)法检测供受者IL-18基因SNP-607 C/A和-137 G/C,分析供受者IL-18不同基因型对患者造血重建速度、移植物抗宿主病(GVHD)发生率、感染发生率、移植相关死亡(TRM)和无病生存(DFS)率的影响.结果 供者-137 G/G与G/C+C/C组比较,allo-HSCT后患者中位粒细胞重建时间较短[15(11～23)d对17(11～24)d,P=0.010],中位血小板重建时间差异无统计学意义[20(11～46)d对20(7～38)d,P=0.844],广泛型慢性GVHD(cGVHD)发生率较高(20.6％对3.3％,P=0.029);供者-607 C/C组广泛型cGVHD发生率高于-607 C/A+A/A组(31.6％对10.8％,P=0.024);受者-607 C/C组广泛型cGVHD发生率高于-607 C/A+A/A组(33.3％对10.7％,P=0.016).不同供受者IL-18基因型组间复发率、TRM、DFS率差异均无统计学意义(P值均＞0.05).结论 选择IL-18-137 G/G基因型供者有助于恶性血液病患者HLA匹配同胞供者allo-HSCT后粒细胞造血重建,但广泛型cGVHD发生率较高.
目的 研究IL-18基因啟動子區單覈苷痠多態性(SNP)對噁性血液病患者HLA匹配同胞供者異基因造血榦細胞移植(allo-HSCT)造血重建、併髮癥及生存的影響.方法 93例噁性血液病患者納入研究.採用序列特異性引物聚閤酶鏈反應(PCR-SSP)法檢測供受者IL-18基因SNP-607 C/A和-137 G/C,分析供受者IL-18不同基因型對患者造血重建速度、移植物抗宿主病(GVHD)髮生率、感染髮生率、移植相關死亡(TRM)和無病生存(DFS)率的影響.結果 供者-137 G/G與G/C+C/C組比較,allo-HSCT後患者中位粒細胞重建時間較短[15(11～23)d對17(11～24)d,P=0.010],中位血小闆重建時間差異無統計學意義[20(11～46)d對20(7～38)d,P=0.844],廣汎型慢性GVHD(cGVHD)髮生率較高(20.6％對3.3％,P=0.029);供者-607 C/C組廣汎型cGVHD髮生率高于-607 C/A+A/A組(31.6％對10.8％,P=0.024);受者-607 C/C組廣汎型cGVHD髮生率高于-607 C/A+A/A組(33.3％對10.7％,P=0.016).不同供受者IL-18基因型組間複髮率、TRM、DFS率差異均無統計學意義(P值均＞0.05).結論 選擇IL-18-137 G/G基因型供者有助于噁性血液病患者HLA匹配同胞供者allo-HSCT後粒細胞造血重建,但廣汎型cGVHD髮生率較高.
목적 연구IL-18기인계동자구단핵감산다태성(SNP)대악성혈액병환자HLA필배동포공자이기인조혈간세포이식(allo-HSCT)조혈중건、병발증급생존적영향.방법 93례악성혈액병환자납입연구.채용서렬특이성인물취합매련반응(PCR-SSP)법검측공수자IL-18기인SNP-607 C/A화-137 G/C,분석공수자IL-18불동기인형대환자조혈중건속도、이식물항숙주병(GVHD)발생솔、감염발생솔、이식상관사망(TRM)화무병생존(DFS)솔적영향.결과 공자-137 G/G여G/C+C/C조비교,allo-HSCT후환자중위립세포중건시간교단[15(11～23)d대17(11～24)d,P=0.010],중위혈소판중건시간차이무통계학의의[20(11～46)d대20(7～38)d,P=0.844],엄범형만성GVHD(cGVHD)발생솔교고(20.6％대3.3％,P=0.029);공자-607 C/C조엄범형cGVHD발생솔고우-607 C/A+A/A조(31.6％대10.8％,P=0.024);수자-607 C/C조엄범형cGVHD발생솔고우-607 C/A+A/A조(33.3％대10.7％,P=0.016).불동공수자IL-18기인형조간복발솔、TRM、DFS솔차이균무통계학의의(P치균＞0.05).결론 선택IL-18-137 G/G기인형공자유조우악성혈액병환자HLA필배동포공자allo-HSCT후립세포조혈중건,단엄범형cGVHD발생솔교고.
Objective To explore the impact of interleukin-18 (IL-18) single nucleot1de polymorphisms on outcomes of hematologic malignances with HLA-matched sibling donor hematopoietic stem cell transplantation (allo-HSCT).Methods Single-nucleotide polymorphisms in IL-18 promoter was detected by PCR-sequence-specific primer analysis (PCR-SSP) in 93 recipients and their HLA matched sibling donors.Hematopoietic reconstitution,incidences of graft versus host disease (GVHD) and infections,transplant related mortality (TRM),and disease free survival (DFS) were analyzed.Results In comparison with-137 G/C+C/C donor genotype,patients with-137 G/G donor genotype had shorter duration of neutrophil recovery [15 (11-23) days vs 17 (11-24) days,P=0.01],higher incidence of extensive chronic GVHD (20.6％ vs 3.3％,P=0.029),but no difference in the interval of platelet recovery [20 (11-46) days vs 20(7-38) days,P=0.844].The incidence of extensive chronic GVHD in-607 C/C donor genotype (31.6％) was significantly higher than that (10.8％) in C/A+A/A donor genotype (P=0.024).Recipients with-607 C/C genotype also had higher incidence (33.3％) of extensive chronic GVHD than those with C/A+A/A genotype (10.7％,P=0.016).There were no differences in acute GVHD,TRM,and DFS between different genotypes.Conclusion IL-18-137 G homozygous genotype in donor facilitated neutrophil reconstitution,but increased the risk of extensive chronic GVHD in patients with alloHSCT.
